MDM2 oncogene as a novel target for human cancer therapy

Current Pharmaceutical Design

Volumn 6, Issue 4, 2000, Pages 393-416

  Zhang, Ruiwen ^a,b   Wang, Hui ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR E2F;

CANCER GROWTH; CANCER THERAPY; DNA DAMAGE; GENE AMPLIFICATION; GENE THERAPY; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0034044571     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612003400911     Document Type: Review

References (21)

1. Prives, C. ; Hall, P. A . The p53 Pathway. J. Pathol. 1999, 187, 112-126.
2. Cahilly-Snyder, L.; Yang, F. T.; Francke, U.; George, D.L. Molecular Analysis and Chromosomal Mapping of Amplified Genes Isolated from a Transformed Mouse 3T3 Cell Line. Somat. Cell Mol. Genet. 1987, 13, 235-244.
3. Fakharzadeh, S. S.; Trusko, S. P.; George, D. L. Tumorigenic Potential Associated with Enhanced Expression of a Gene that is Amplified in a Mouse Tumor Cell Line. EMBO J. 1991, 10, 1565-1569.
4. Piette, J.; Neel, H.; Marechal, V. Mdm2: Keeping p53 under Control. Oncogene 1997, 15, 1001-1010.
5. Momand, J.; Zambetti, G. P. Mdm-2: "Big Brother" of p53. J. Cell Biochem. 1997, 64, 343-352.
6. El-Deiry, W. S. Role of Oncogenes in Resistance and Killing by Cancer Therapeutic Agents. Curr. Opin. Oncol. 1997, 9, 79-87.
7. Prives, C. Signaling to p53: Breaking the MDM2-p53 Circuit. Cell 1998, 95, 5-8.
8. Lozano, G.; Montes de Oca Luna, R. MDM2 Function.Biochim. Biophys.Acta 1998, 1377, M55-M59.
9. Juven-Gershon, T.; Oren, M. Mdm2, the Ups and Downs. Mol. Med. 1999, 5, 71-83.
10. Freedman, D. A.; Wu, L.; Levine, A. J. Functions of the MDM2 Oncoprotein. Cell. Mol. Life Sci. 1999, 55, 96-107.
11. Freedman, D.A.; Levine, A. J. Regulation of p53 Protein by MDM2 Oncoprotein-Thirty Eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res. 1999, 59, 1-7.
12. Linzer, D. I. H.; Levine, A. J. Characterization of a 54K Dalton Cellular SV40 Tumor Antigen Present in SV40-transformed Cells and Uninfected Embryonal Carcinoma Cells. Cell 1979, 17, 43-52.
13. Lane, D. P.; Crawford, L. V. T Antigen is Bound to a Host Protein in SV40-transformed Cells. Nature 1979, 278, 261-263.
14. Oren, M.; Levine, A.J. Molecular Cloning of a cDNA Specific for the Murine p53 Cellular Tumor Antigen. Proc. Natl. Acad. Sci. USA. 1983, 80, 56-59.
15. Pennica, D.; Goeddel, D. V.; Hayflick, J. S.; Reich, N. C.; Anderson, C. W.; Levine, A.J. The Amino Acid Sequence of Murine p53 Determined from a cDNA Clone. Virology 1984, 134, 477-482.
16. Zakut-Houri, R.; Bienz-Tadmor, B.; Givol, D.; Oren, M. Human P53 Cellular Tumor Antigen, cDNA Sequence and Expression in COS Cells. EMBO J. 1983, 4, 1251-1255.
17. Hinds, P.; Finlay, C.; Levine, A. J. Mutation is Required to Activate the p53 Gene for Cooperation with ras Oncogene and Transformation. J. Virol. 1989, 63, 739-746.
18. Finlay, C.; Hinds, P.; Levine, A. J. The p53 Proto-oncogene Can Act as a Suppressor of Transformation. Cell 1989, 57, 1083-1093.
19. Baker, S. J.; Fearon, E. R.; Nigro, J. M.; Hamilton, S. R.; Preisinger, A. C.; Jessup, J. M.; Van Tuinen, P.; Ledbetter, D. H.; Barker, D. F.; Nakamura, Y.; White, R.; Vogelstein, B. Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas. Science 1989, 244, 217-221.
20. Nigro, J. M.; Baker, S. J.; Preisinger, A. C.; Jessup, J. M.; Hostetter, R.; Cleary, K.; Bigner, S. H.; Davidson, N.; Baylin, S.; Devilee, P.; Glover, T.; Collins, F. S.; Weston, A.; Modali. R.; Harris, C. C.; Vogelstein, B. Mutations in the p53 Gene Occur in Diverse Human Tumor Types. Nature 1989, 342, 705-708.
21. Okamoto, K.; Beach, D. Cyclin G is a Transcriptional Target of the p53 Tumor Suppressor Protein. EMBO J. 1994, 13, 4816-4822.